Access to Liposomal Generic Formulations: Beyond AmBisome and Doxil/Caelyx

GaBI Journal - Belgium
doi 10.5639/gabij.2013.0202.022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pro Pharma Communications International

Related search

Pharmacokinetics of Liposomal Amphotericin B (Ambisome) in Critically Ill Patients.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

99mTc-Labelled Stealth® Liposomal Doxorubicin (Caelyx®) in Glioblastomas and Metastatic Brain Tumours

British Journal of Cancer
Cancer ResearchOncology
2002English

Generic Clozapine: Outcomes After Switching Formulations

British Journal of Psychiatry
MedicinePsychiatryMental Health
2006English

Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions

Clinical Infectious Diseases
Infectious DiseasesMicrobiology
1995English

Generic Approach to Access Barriers in Dehydrogenation Reactions

Communications Chemistry
BiochemistryEnvironmental ChemistryMaterials ChemistryChemistry
2018English

Bioavailability and Dissolution of Proprietary and Generic Formulations of Phenytoin.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1992English

Beyond Lebesgue and Baire: Generic Regular Variation

Colloquium Mathematicum
Mathematics
2009English

Quality Evaluation of Original and Generic Formulations of Iopamidol Injection

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2007English

Generic Modified-Release Antiepileptic Drugs: No Difference Within Formulations, but Important Differences Across Formulations

Epilepsy Currents
Neurology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy